Company intelligence / Profile preview

Parvus Therapeutics

South San Francisco, California, United Statesdnb.com ↗

Ownership: Private
Development stage: Other

Overview

Parvus Therapeutics is developing a novel class of disease-modifying therapeutics called Navacims that use pMHC nanomedicines to induce antigen-specific regulatory T cells in vivo. This approach aims to restore immune tolerance and reverse autoimmune disease without broad immunosuppression. The company has demonstrated efficacy in multiple animal models and is advancing several drug candidates through preclinical development into the clinic. No active clinical trials are currently registered on ClinicalTrials.gov as of January 2025.

Therapeutic areas: EndocrinologyImmunology
Modalities: Nanoparticle (pMHC nanomedicine)Biologic (Navacims)
Industry: Biotech

Partnerships

No major pharmaceutical partnerships disclosed publicly as of June 2025.

Beyond the preview

Go deeper on Parvus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parvus Therapeutics.

Explore the full profile